Haemonetics (HAE)
(Delayed Data from NYSE)
$90.99 USD
+3.33 (3.80%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $91.00 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HAE 90.99 +3.33(3.80%)
Will HAE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HAE
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
HAE vs. ABT: Which Stock Is the Better Value Option?
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval
Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
Other News for HAE
Haemonetics (HAE) Shares Cross Above 200 DMA
Haemonetics Poised for Growth with Strong Q4 Projections and Strategic Acquisitions
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
Royce Investment Partners Commentary: What Will Fuel Small-Cap Returns?
Haemonetics Receives FDA Clearance for New TEGĀ® 6s Global Hemostasis - HN Cartridge